NGS precision medicine market seen reaching $14.05 billion by 2030

Next-generation sequencing in precision medicine is projected to grow from $6.42 billion in 2025 to $14.05 billion by 2030, driven by AI, cloud tools and broader use in clinical research. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Next-generation sequencing is becoming a core tool for precision medicine by helping clinicians and researchers read genetic and RNA data faster and in more detail. - The market’s projected jump to $14.05 billion by 2030 points to stronger demand for personalized diagnosis, treatment selection and genomic research infrastructure. - Growing genetic disorder detection is increasing the need for sequencing-based testing and earlier intervention.

What happened: - The Business Research Company said the next-generation sequencing in precision medicine market will rise from $6.42 billion in 2025 to $7.52 billion in 2026. - The market is projected to reach $14.05 billion by 2030, implying a 16.9% compound annual growth rate from 2026 to 2030. - The report was released Aug. 19, 2026, from London. - The company also made the report available through a free sample and the full market report.

The details: - Market growth in the near term has been tied to high-throughput sequencing advances, rising awareness of personalized medicine, expanding genomic research, growth in bioinformatics software and wider use of precision medicine in clinical trials. - Future expansion is expected to be supported by better sequencing instruments, artificial intelligence in genomics, cloud-based sequencing services, pharma-biotech collaboration and broader adoption in emerging markets. - Expected trends include AI-powered genomic analysis, cloud-based sequencing solutions, automation in sequencing workflows, real-time interpretation of genomic data and continued growth in personalized medicine. - Next-generation sequencing is described as a technology that analyzes DNA and RNA on a faster and larger scale than traditional methods. - The technology supports precision medicine by helping identify individual genetic variations and molecular profiles. - Those datasets can support more tailored decisions on diagnosis, treatment and outcomes. - Genetic disorder prevalence is a key demand driver because improved screening is uncovering cases that were previously missed. - The National Health Service said in May 2024 that about 17,000 people in England live with sickle cell disease and about 250 new cases are diagnosed each year. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests sequencing is moving from a specialized research tool toward a broader clinical and commercial platform. - AI and cloud services are emerging as the biggest efficiency levers because they can reduce analysis time and make genomic data easier to use at scale. - Regional growth is likely to track healthcare spending and research investment, which helps explain North America’s lead and Asia-Pacific’s faster growth outlook. - The report’s added market-attractiveness scoring, TAM analysis and forecasting dashboards indicate the sector is being positioned for more competitive investment decisions.

What's next: - Expect more adoption of cloud-based and AI-assisted sequencing systems as healthcare providers and research groups seek faster interpretation. - Drugmakers and biotech firms are likely to deepen partnerships around genomics-driven research and trial design. - Emerging markets may become a larger growth engine as precision medicine spreads beyond mature healthcare systems.

The bottom line: - NGS in precision medicine is moving into a higher-growth phase, with technology upgrades and broader clinical use set to drive the market toward $14.05 billion by 2030.